---

Therapeutics, Biotechnology, Life Science

Scribe Therapeutics is a biotech company that develops and engineers new therepeutics based on CRISPR.

Alameda, California, United States, North America (US)

Organizations in Alameda in Therapeutics,
Organizations in Alameda in Biotechnology,
Organizations in Alameda in Life Science,
Organizations in California in Therapeutics,
Organizations in California in Biotechnology,
Organizations in California in Life Science,
Organizations in United States in Therapeutics,
Organizations in United States in Biotechnology,
Organizations in United States in Life Science,
Organizations in North America in Therapeutics,
Organizations in North America in Biotechnology,
Organizations in North America in Life Science

Investors in Alameda in Therapeutics,
Investors in Alameda in Biotechnology,
Investors in Alameda in Life Science,
Investors in California in Therapeutics,
Investors in California in Biotechnology,
Investors in California in Life Science,
Investors in United States in Therapeutics,
Investors in United States in Biotechnology,
Investors in United States in Life Science,
Investors in North America in Therapeutics,
Investors in North America in Biotechnology,
Investors in North America in Life Science

West Coast (0 Investors) (0 Startups), Western US (0 Investors) (0 Startups), San Francisco Bay Area (0 Investors) (0 Startups)

Founded date 01, 2018

Founders Brett Staahl, David F. Savage, Jennifer Doudna, Benjamin Oakes

Operating Status Active

Funding Stage Early Stage Venture

Last Funding Type Series A

Company Type For Profit

---

Scribe Therapeutics is a biotech company that develops and engineers new therapeutics based on CRISPR. The company’s first technology, called X-Editing (XE) molecules, are highly engineered CRISPR enzymes that provide combined aspects of greater efficacy, specificity, and deliverability than currently available CRISPR genome editing technology. It also a long-term, engineering approach that can help establish CRISPR-based therapies as a new standard of clinical care and expand access to groundbreaking treatments that will impact millions of lives. Scribe Therapeutics is overcoming the limitations of current genome editing technologies by developing custom-engineered enzymes and delivery modalities as part of a proprietary, evergreen platform for CRISPR-based genetic medicine. The company built for exceptional specificity within the genome – enabling therapeutic precision and allele-specific targeting. Scribe Therapeutics was founded in 2018 and is headquartered in Alameda, CA, USA.

---

Scribe Therapeutics Investors (10)